Risk prediction model of dyslipidaemia over a 5-year period based on the Taiwan MJ health check-up longitudinal database

ObjectiveThis study aimed to provide an epidemiological model to evaluate the risk of developing dyslipidaemia within 5 years in the Taiwanese population.MethodsA cohort of 11,345 subjects aged 35–74 years and was non-dyslipidaemia in the initial year 1996 and followed in 1997–2006 to derive a risk score that could predict the occurrence of dyslipidaemia. Multivariate logistic regression was used to derive the risk functions using the check-up centre of the overall cohort. Rules based on these risk functions were evaluated in the remaining three centres as the testing cohort. We evaluated the predictability of the model using the area under the receiver operating characteristic (ROC) curve (AUC) to confirm its diagnostic property on the testing sample. We also established the degrees of risk based on the cut-off points of these probabilities after transforming them into a normal distribution by log transformation.ResultsThe incidence of dyslipidaemia over the 5-year period was 19.1%. The final multivariable logistic regression model includes the following six risk factors: gender, history of diabetes, triglyceride level, HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol) and BMI (body mass index). The ROC AUC was 0.709 (95% CI: 0.693–0.725), which could predict the development of dyslipidaemia within 5 years.ConclusionThis model can help individuals assess the risk of dyslipidaemia and guide group surveillance in the community.

[1]  Hui Ting Chan,et al.  All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan , 2008, The Lancet.

[2]  Yuehua Wu,et al.  The prevalence, awareness, treatment and control of dyslipidemia among adults in China. , 2016, Atherosclerosis.

[3]  D. A. Rowe,et al.  Associations between metabolic syndrome components and markers of inflammation in Welsh school children , 2017, European Journal of Pediatrics.

[4]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[5]  Terje R Pedersen,et al.  Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. , 2016, International journal of cardiology.

[6]  A. Sumner.  Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. , 2009, The Journal of pediatrics.

[7]  R. Cífková,et al.  Dyslipidemia and Cardiovascular Disease in Women , 2015, Current Cardiology Reports.

[8]  Á. Carracedo,et al.  Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[9]  L. Rallidis,et al.  Serum interleukin‐6 is elevated in symptomatic carotid bifurcation disease , 2009, Acta neurologica Scandinavica.

[10]  [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. , 2007, Zhonghua xin xue guan bing za zhi.

[11]  M. Rizzo,et al.  Prevalence of dyslipidemia and associated risk factors in Turkish adults. , 2014, Journal of clinical lipidology.

[12]  Ariel Linden.  Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. , 2006, Journal of evaluation in clinical practice.

[13]  Juan Yang,et al.  Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients , 2010, Acta Pharmacologica Sinica.

[14]  M. Clearfield.  C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease , 2005, The Journal of the American Osteopathic Association.

[15]  F. Gutzwiller,et al.  Trends in cardiovascular risk factors (1984-1993) in a Swiss region: results of three population surveys. , 1997, Preventive medicine.

[16]  N. Chu,et al.  Prevalence and trend of dyslipidaemia from 1996 to 2006 among normal and overweight adolescents in Taiwan , 2014, BMJ Open.

[17]  A. Gotto,et al.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. , 2004, Journal of the American College of Cardiology.

[18]  A. Hata,et al.  Predictive Power of a Body Shape Index for Development of Diabetes, Hypertension, and Dyslipidemia in Japanese Adults: A Retrospective Cohort Study , 2015, PloS one.

[19]  M. Woodward,et al.  By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease , 2005, Heart.

[20]  S. Lai,et al.  Prevalence of Dyslipidemia in Patients Receiving Health Checkups: A Hospital-Based Study , 2011, Cholesterol.

[21]  Ling Wang,et al.  Development and Evaluation of a Simple and Effective Prediction Approach for Identifying Those at High Risk of Dyslipidemia in Rural Adult Residents , 2012, PloS one.

[22]  V. L. Clark,et al.  Clinical Methods: The History, Physical, and Laboratory Examinations , 1990 .

[23]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[24]  P. Alagona,et al.  The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. , 2012, Journal of the American College of Cardiology.

[25]  Yuanxiu Huang,et al.  Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control , 2014, Population Health Metrics.

[26]  M. Szklo,et al.  Racial/ethnic differences in the association of triglycerides with other metabolic syndrome components: the Multi-Ethnic Study of Atherosclerosis. , 2011, Metabolic syndrome and related disorders.

[27]  S. Zhan,et al.  An accurate risk score for estimation 5-year risk of type 2 diabetes based on a health screening population in Taiwan. , 2009, Diabetes research and clinical practice.

[28]  M. Woodward,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002 , 2008, Circulation.

[29]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[30]  J. Viikari,et al.  Adult dyslipidemia prediction is improved by repeated measurements in childhood and young adulthood. The Cardiovascular Risk in Young Finns Study. , 2015, Atherosclerosis.

[31]  Lihua Chen,et al.  Association between alcohol intake, overweight, and serum lipid levels and the risk analysis associated with the development of dyslipidemia. , 2014, Journal of clinical lipidology.

[32]  R. Habib,et al.  Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia. , 2014, Annals of vascular surgery.

[33]  Te-Wei Ho,et al.  Disease-Free Survival after Hepatic Resection in Hepatocellular Carcinoma Patients: A Prediction Approach Using Artificial Neural Network , 2012, PloS one.

[34]  Katsuhisa Horimoto,et al.  Plasma Free Amino Acid Profiles Predict Four-Year Risk of Developing Diabetes, Metabolic Syndrome, Dyslipidemia, and Hypertension in Japanese Population , 2015, Scientific Reports.

[35]  P. Jose,et al.  Racial/Ethnic Differences in Dyslipidemia Patterns , 2014, Circulation.

[36]  H Kenneth Walker,et al.  Clinical methods: The history, physical, and laboratory examinations , 1976 .

[37]  A. Dobrian,et al.  Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease , 2013, Diabetes, obesity & metabolism.

[38]  Eugene Lin,et al.  Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms. , 2010, Advances and applications in bioinformatics and chemistry : AABC.